changing the surface
of biotechnology

Kode Technology (FSL constructs) adds new functions to virtually any surface, living or inert, without harming living cells.

Biosurface engineering has never been easier.

1996

Founded in New Zealand to develop, commercialise and license Kode Technology

20+ years

Designing, making and selling FSL constructs

600+

Research probes, including FSL constructs

Global

Distribution through GlycoNZ and Merck MilliporeSigma

Kode Technology: biosurface engineering

Cells, bacteria and viruses recognise each other through shapes on their surfaces. Kode Biotech builds those shapes, and other functions, onto a lipid tail that sticks like paint to living and non-living surfaces, changing how they interact.

more on FSL constructs
What is Kode Technology?a biosurface engineering paint
Read the transcript

Imagine a paint that uses shapes to prevent and cure illness. It's now possible.

Your body is filled with 37 trillion cells, 40 trillion bacteria, and often lots of viruses. They all look different and do different things, and can interact with each other through connecting shapes on each other's surfaces. Sometimes interactions can be good, like sperm finding an egg, or bad, like a virus causing the flu.

Imagine if we could change these interactions. Well, now we can, with Kode paint. Remember those shapes that the cell and the virus used to interact? We can copy them. And then we can attach a special tail on them that can stick, like paint, to a surface. There are lots of different paints we can make from shapes on cells, bacteria and viruses. All of this means scientists can do faster, better, smarter research to help change the future of medicine.

So what could Kode mean for you? We can help your medicine find the right place. Or stop you getting infections after surgery. Or make your bandage heal you faster. Or train a virus to find and kill your cancer. Or even teach your body to do it itself.

Painting the future. Kode Biotech and AUT.

Kode Technology is established: FSL constructs have been designed, made and sold for more than 20 years, and are used in research laboratories and blood-bank quality-control products worldwide. The medical uses at the end of this video are investigational research directions: none is approved by a medicines regulator. Investigational disclaimer

Kode Technology for scientists: explore the science

The Kode Technology Illustrated Technical Manual brings all known Kode Technology data together in one illustrated reference, free to download. Stephen Henry's DSc thesis, the peer-reviewed papers and the full bibliography go further.

University of Auckland National Library of NZ

Science and Publications · Downloads

Cover of the Kode Technology Illustrated Technical Manual, first edition, 2023

Kode Immunoeducers: cancer immunotherapy

An adjuvant-like initiator of an in situ autologous cancer vaccine. The KIE supplies the immune-initiating signal; the patient's tumour supplies the tumour antigens.

AGI-134Gen 2 · Kode Agalimmune
Human oncology
Kv9Gen 3 · Kode Veterinary Sciences
Veterinary oncology
K5KGen 3 · KodeRx
Human oncology

K5K and Kv9 are Gen 3 KIE molecules, identical by structure. All KIE programmes are investigational.

more on Kode Immunoeducers

Kode Group: one body of science

Kode Biotech is the holder and parent of companies that license Kode Technology for different sectors and uses. The group also includes GlycoNZ, which supplies a broad range of glycoconjugate research probes, including FSL constructs.

more on the Kode Group

Our partners: working together

Kode Biotech works with distributors, suppliers and charitable partners to take Kode Technology further.

Equitable Oncology

Independent New Zealand charity helping more people access cancer treatment. K5K is the first programme selected to progress through its model.

Merck MilliporeSigma

Global distributor of Kode FSL constructs and other research glycoconjugates.

Synpel Chemical

A Czech Republic chemical manufacturer that makes Kode FSL and GlycoNZ products.

Other partners

Research, manufacturing, and sales and distribution partners.

all our partners

Kode Biotech timeline: three decades

From a New Zealand start-up in 1996 to a group of companies advancing Kode Technology for research, diagnostics and cancer immunotherapy, and supplying glycan research probes worldwide.

1996KBL founded
2005First diagnostic product
2010Sigma-Aldrich catalogue
Gen 2AGI-134
Gen 3K5K and Kv9
TodayGroup of companies
EOL partnership
the full timeline

Work with us: partner with kode

Licensing, research collaboration and custom FSL constructs.